Fundraising Fox

LumiThera

Poulsbo, US · Founded 2013 · Delaware corporation · 4 known investors

LumiThera develops the Valeda Light Delivery System, an FDA-authorized photobiomodulation (PBM) device that applies multiple light wavelengths to treat early and intermediate dry age-related macular degeneration (AMD). The non-invasive treatment is intended for eyecare practitioners to help patients maintain or improve visual acuity.

BiotechHealthtechMedical Devices

Founders & leadership

TP
Tracy PuckettExecutive
CT
Clark TedfordExecutive
SBScott Bradley
Scott BradleyExecutive
DM
Duane MorrisonExecutive
CCCindy Croissant
Cindy CroissantExecutive
RM
Ryan MontecuccoExecutive
AT
Art TaylorNamed on SEC filing
GM
Graham MerryNamed on SEC filing
RD
Robert DotsonNamed on SEC filing

Board

DB
Daniel BertholetBoard director
YY
Yang YigangBoard director
SC
Shupeng CaoBoard director

Investors · 4

3E Bioventures CapitalPalo Alto
Life Sciences Greenhouse InvestmentsHarrisburg · $250K – $500K
Imagine VenturesreportedSantiago
Keiretsu CapitalreportedSeattle

Reported raises · per SEC filings

Form D private placements

$25.5M disclosed across 9 rounds · 2014–2024

▶$10MraisedFeb 2025 · 58 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Tracy PuckettExecutive Officer
  • Daniel BertholetDirector
  • Clark TedfordExecutive Officer, Director
  • Jackson StreeterDirector
  • Scott BradleyExecutive Officer
  • Duane MorrisonExecutive Officer
  • Cindy CroissantExecutive Officer
  • Ryan MontecuccoExecutive Officer
  • Yang YigangDirector
  • Shupeng CaoDirector
Offering amount
$10M
Amount sold
$10M
Minimum investment
$10K
Sales commissions
$22.7K
Placement agents
Entoro Securities
First sale
May 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$820KraisedSep 2022 · 7 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Joseph FontanettaDirector
  • Cindy CroissantExecutive Officer
  • Shupeng CaoDirector
  • Daniel BertholetDirector
  • Duane MorrisonExecutive Officer
  • Tracy PuckettExecutive Officer
  • Todd ChristieDirector
  • Clark TedfordExecutive Officer, Director
  • Scott BradleyExecutive Officer
  • Jackson StreeterDirector
  • Ryan MontecuccoExecutive Officer
  • Yang YigangDirector
Offering amount
$2M
Amount sold
$820K
Minimum investment
$25K
First sale
Sep 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.5MraisedOct 2021 · 56 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Duane MorrisonExecutive Officer
  • Scott BradleyExecutive Officer
  • Cindy CroissantExecutive Officer
  • Yang YigangDirector
  • Clark TedfordExecutive Officer, Director
  • Ryan MontecuccoExecutive Officer
  • Daniel BertholetDirector
Offering amount
$8.1M
Amount sold
$4.5M
Minimum investment
$15K
Finders' fees
$101.1K
Placement agents
Entoro Securities
First sale
Dec 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.1MraisedAug 2019 · 8 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • YIGANG YANGDirector
  • CLARK TEDFORDExecutive Officer, Director
  • ARTHUR TAYLORDirector
Offering amount
$10M
Amount sold
$1.1M
Minimum investment
$10K
Sales commissions
$7K
Placement agents
COVA CAPITAL PARTNERS LLC
First sale
Jun 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$100KraisedMar 2019 · 1 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • YIGANG YANGDirector
  • CLARK TEDFORDExecutive Officer, Director
  • ARTHUR TAYLORDirector
Offering amount
$2M
Amount sold
$100K
Minimum investment
$50K
Sales commissions
$7K
Placement agents
KEVIN CODY
First sale
Feb 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedJan 2019 · 13 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Art TaylorDirector
  • Yang YigangDirector
  • Clark TedfordExecutive Officer, Director
Offering amount
$2M
Amount sold
$2M
Minimum investment
$10K
First sale
Dec 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.6MraisedAug 2018 · 18 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Art TaylorDirector
  • Yang YigangDirector
  • Clark TedfordExecutive Officer, Director
Offering amount
$2M
Amount sold
$1.6M
Minimum investment
$25K
First sale
Mar 2018
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedOct 2017 · 51 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Art TaylorDirector
  • Clark TedfordExecutive Officer, Director
Offering amount
$6.6M
Amount sold
$5M
Minimum investment
$10K
Sales commissions
$7K
Proceeds to insiders
$240K
Placement agents
Robert Brisotti
First sale
Nov 2016
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 5 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2023$1.2M
National Institutes of Health (NIH)National Institutes of HealthPhase II2020$1.8M
National Institutes of Health (NIH)National Institutes of HealthPhase II2019$2.5M
National Institutes of Health (NIH)National Institutes of HealthPhase I2015$396K
National Institutes of Health (NIH)National Institutes of HealthPhase I2015$356.9K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Medical device startup LumiThera raises $14M to further develop treatment for ocular disorders – GeekWiregeekwire.com · Jul 2020LumiThera Raises $14M in Series C Financing - FinSMEsfinsmes.com · Jul 2020LumiThera Closes 2nd Tranche of Series C Financing - BioSpacebiospace.com · Jan 2020LumiThera raises cash for medical device that uses light to fight vision loss – GeekWiregeekwire.com · Aug 2019LumiThera raises $6m in Series B - MassDevicemassdevice.com · Oct 2017

Frequently asked questions

What does LumiThera do?
LumiThera develops the Valeda Light Delivery System, an FDA-authorized photobiomodulation (PBM) device that applies multiple light wavelengths to treat early and intermediate dry age-related macular degeneration (AMD). The non-invasive treatment is intended for eyecare practitioners to help patients maintain or improve visual acuity.
Who are LumiThera's investors?
LumiThera's investors include 3E Bioventures Capital, Life Sciences Greenhouse Investments, Imagine Ventures, Keiretsu Capital.
How much funding has LumiThera raised?
LumiThera has disclosed $25.5M raised across 9 rounds.
Where is LumiThera headquartered?
LumiThera is headquartered in Poulsbo, US.